Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% during the 4th quarter, Holdings Channel reports. The fund owned 76,472 shares of the biopharmaceutical company’s stock after purchasing an additional 674 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Halozyme Therapeutics were worth $2,826,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Tritonpoint Wealth LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $250,000. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $1,030,000. Assenagon Asset Management S.A. grew its holdings in Halozyme Therapeutics by 76.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 125,207 shares of the biopharmaceutical company’s stock valued at $4,628,000 after purchasing an additional 54,063 shares during the period. Pacer Advisors Inc. grew its holdings in Halozyme Therapeutics by 137.3% in the fourth quarter. Pacer Advisors Inc. now owns 26,376 shares of the biopharmaceutical company’s stock valued at $975,000 after purchasing an additional 15,261 shares during the period. Finally, FCF Advisors LLC grew its holdings in Halozyme Therapeutics by 431.4% in the fourth quarter. FCF Advisors LLC now owns 20,773 shares of the biopharmaceutical company’s stock valued at $768,000 after purchasing an additional 16,864 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the transaction, the senior vice president now owns 156,558 shares in the company, valued at $6,519,075.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 30,000 shares of company stock worth $1,196,800. 2.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on HALO. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. The Goldman Sachs Group dropped their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. Morgan Stanley lowered their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $38.02 on Thursday. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The business’s 50 day moving average price is $39.44 and its 200-day moving average price is $37.76. The firm has a market capitalization of $4.83 billion, a PE ratio of 18.02, a P/E/G ratio of 0.47 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.